V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210002803 | 210011361 | 1.66 | 58.6 | null | 2019-12-01 | 2019-12-22 | EC | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100331790 |
| 210002804 | 210011362 | 1.67 | 78.6 | Palliative (P) | 2016-12-15 | 2017-02-23 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100294758 |
| 210002806 | 210011364 | 1.64 | 69.6 | Adjuvant (A) | 2018-09-22 | 2018-10-23 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101280102 |
| 210002808 | 210011365 | 1.61 | 90 | Adjuvant (A) | null | 2022-05-27 | Trastuzumab 21 day maintenance | 02 | N | TRASTUZUMAB | 100176034 |
| 210002811 | 210011366 | 1.64 | 98.8 | Neo-adjuvant (N) | null | 2019-03-17 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 101738903 |
| 210002812 | 210011367 | 1.59 | 75 | Adjuvant (A) | 2019-07-19 | 2019-09-14 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 101372776 |
| 210002813 | 210011368 | 1.69 | 58.1 | Adjuvant (A) | 2020-02-04 | 2020-02-14 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 100931928 |
| 210002815 | 210011369 | 0.8 | 119 | Neo-adjuvant (N) | 2019-02-17 | 2019-04-29 | Trastuzumab | 02 | N | TRASTUZUMAB | 100882474 |
| 210002816 | 210011370 | 1.63 | 77 | Adjuvant (A) | 2019-05-24 | 2019-08-11 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101568694 |
| 210002818 | 210011372 | null | null | Adjuvant (A) | 2016-03-22 | 2016-12-28 | TRASTUZUMAB | N | N | TRASTUZUMAB | 101143154 |
| 210002819 | 210011373 | 1.52 | 84.3 | Adjuvant (A) | 2019-07-31 | 2019-08-15 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100297554 |
| 210002820 | 210011374 | 1.48 | 96 | Adjuvant (A) | null | 2021-01-09 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100906082 |
| 210002822 | 210011375 | null | 76.8 | Adjuvant (A) | 2017-09-08 | 2018-02-05 | Docetaxel | null | N | DOCETAXEL | 100138316 |
| 210002828 | 210011377 | 1.66 | 78.6 | Neo-adjuvant (N) | 2017-10-16 | 2017-10-20 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101782261 |
| 210002836 | 210011381 | 1.66 | 69.4 | Adjuvant (A) | null | 2017-12-20 | Docetaxel 100mg/m2 (21 day) | 02 | N | DOCETAXEL | 100919568 |
| 210002837 | 210011382 | null | 58.5 | null | null | 2019-11-15 | Trastuzumab Subcutaneous | 02 | null | TRASTUZUMAB | 100468296 |
| 210002839 | 210011383 | 1.51 | 55.7 | Adjuvant (A) | null | 2019-12-23 | Trastuzumab | null | null | TRASTUZUMAB | 100661655 |
| 210002840 | 210011384 | 0 | 75.1 | null | 2016-05-29 | 2016-11-30 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101817323 |
| 210002842 | 210011385 | null | null | Adjuvant (A) | 2019-02-16 | 2019-03-28 | Trastuzumab | 02 | N | TRASTUZUMAB | 101791004 |
| 210002843 | 210011386 | 1.59 | 76 | Adjuvant (A) | 2019-06-20 | 2020-03-29 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | PACLITAXEL | 101788009 |
| 210002851 | 210011387 | 1.62 | 72.3 | Adjuvant (A) | null | 2018-11-14 | Trastuzumab | 02 | N | TRASTUZUMAB | 100371474 |
| 210002854 | 210011388 | 1.7 | 63 | Adjuvant (A) | null | 2017-12-04 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100773920 |
| 210002856 | 210011389 | 1.55 | 75.5 | null | 2020-05-20 | 2020-06-21 | Trastuzumab | 01 | N | TRASTUZUMAB | 101220719 |
| 210002857 | 210011390 | 1.58 | 74.4 | Neo-adjuvant (N) | 2017-04-11 | 2017-08-14 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100075132 |
| 210002861 | 210011391 | 1.74 | 73.5 | Adjuvant (A) | null | 2018-07-04 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 101578111 |
| 210002862 | 210011392 | null | 45.2 | null | 2018-12-06 | 2018-12-11 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101200039 |
| 210002863 | 210011393 | 1.58 | 75.6 | Neo-adjuvant (N) | 2021-11-03 | 2021-11-05 | Docetaxel | 02 | N | DOCETAXEL | 100688876 |
| 210002870 | 210011395 | 1.72 | 55.6 | Palliative (P) | null | 2020-04-18 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | PACLITAXEL | 100198080 |
| 210002876 | 210011398 | 1.76 | 55.2 | Adjuvant (A) | null | 2020-01-18 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100271841 |
| 210002878 | 210011399 | 1.64 | 0 | null | 2017-01-12 | 2017-05-29 | Docetaxel | 02 | null | DOCETAXEL | 101006110 |
| 210002879 | 210011400 | 1.62 | 81 | Palliative (P) | 2016-03-25 | 2016-06-19 | Docetaxel | 02 | N | DOCETAXEL | 101763875 |
| 210002881 | 210011401 | 1.67 | 68.55 | Adjuvant (A) | 2020-02-01 | 2020-02-15 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100216802 |
| 210002886 | 210011403 | 1.54 | 79.4 | Curative (C) | 2017-01-12 | 2017-03-28 | Docetaxel | 02 | N | DOCETAXEL | 100675150 |
| 210002887 | 210011404 | 1.55 | 99.1 | Palliative (P) | 2020-07-01 | 2020-12-10 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | PACLITAXEL | 101533304 |
| 210002890 | 210011405 | 1.59 | 79.3 | Palliative (P) | 2020-08-27 | 2021-03-04 | Docetaxel 100mg/m2 (21 day) | N | N | DOCETAXEL | 100921578 |
| 210002895 | 210011407 | 1.78 | 85.1 | Adjuvant (A) | 2017-11-28 | 2017-11-28 | Paclitaxel 7 day | N | N | PACLITAXEL | 101293646 |
| 210002898 | 210011408 | 1.65 | 68.6 | Adjuvant (A) | null | 2020-12-12 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 100974758 |
| 210002906 | 210011410 | 1.73 | 61.3 | null | 2016-03-07 | 2018-11-18 | Docetaxel | 02 | N | DOCETAXEL | 100885329 |
| 210002908 | 210011411 | null | 75.7 | Palliative (P) | null | 2018-08-21 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100285598 |
| 210002910 | 210011412 | 1.62 | 70.6 | Adjuvant (A) | null | 2019-05-10 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100774139 |
| 210002912 | 210011413 | 1.55 | 96.8 | Adjuvant (A) | null | 2019-07-27 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 101686428 |
| 210002917 | 210011416 | null | 72.6 | Palliative (P) | 2018-06-06 | 2018-10-03 | Paclitaxel 7 day | 02 | null | PACLITAXEL | 101308691 |
| 210002921 | 210011418 | null | 86.2 | Neo-adjuvant (N) | 2017-03-13 | 2019-08-28 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | PACLITAXEL | 101822744 |
| 210002922 | 210011419 | null | 103.5 | Neo-adjuvant (N) | null | 2018-05-04 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100940930 |
| 210002924 | 210011420 | 1.68 | 76 | null | 2021-07-08 | 2021-10-24 | Docetaxel 100mg/m2 (21 day) | null | N | DOCETAXEL | 101550346 |
| 210002927 | 210011422 | null | 90.4 | Adjuvant (A) | 2021-02-19 | 2021-04-12 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100597936 |
| 210002930 | 210011423 | 1.65 | 72.9 | null | 2019-01-13 | 2019-02-11 | Docetaxel | 02 | null | DOCETAXEL | 100581865 |
| 210002932 | 210011424 | null | 69.4 | null | null | 2020-12-13 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 100613122 |
| 210002935 | 210011425 | 1.53 | 49.7 | Adjuvant (A) | null | 2019-04-11 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100668526 |
| 210002937 | 210011426 | 1.67 | 60.6 | null | null | 2021-08-09 | Docetaxel | 02 | N | DOCETAXEL | 101655869 |